Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver entities : Intercept pharmaceuticals, inc. save search
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
| Email alert
Add to watchlist
meeting liver impact biomarkers
Global NASH Market to Soar to $2.71 Billion by 2023, Driven by Rising Prevalence of Silent Liver Disease
Published: 2023-11-11 (Crawled : 04:20) - prnewswire.com
IVA | $3.45 4K
|
Health Technology
| Email alert
Add to watchlist
GALT | $3.27 -3.25% 23K
|
Health Technology
| Email alert
Add to watchlist
GNFT | $3.59 1.1K
|
Health Technology
| Email alert
Add to watchlist
ICPT | $19.0 -0.05% 4M
|
Health Technology
| Email alert
Add to watchlist
IVEVF | $3.73 0% 1K
|
n/a
| Email alert
Add to watchlist
NVS | $93.815 1.35% 410K
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
AZN | $68.545 0.27% 1.2M
|
Health Technology
| Email alert
Add to watchlist
MDGL | $216.98 -2.38% 120K
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $138.24 800
|
Health Technology
| Email alert
Add to watchlist
GLMD | $0.3787 7.4K
|
Health Technology
| Email alert
Add to watchlist
liver disease global nash market
Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
| Email alert
Add to watchlist
meeting liver beyond poise extension trial biomarkers
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: 76.15%
H: 1.79%
C: 1.74%
rare liver pharmaceuticals global acquire
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
Published: 2023-06-23 (Crawled : 11:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: 1.21%
H: 2.65%
C: 0.43%
rare liver
Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
Published: 2023-06-23 (Crawled : 07:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: 1.21%
H: 2.65%
C: 0.43%
liver impact biomarkers
Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program
Published: 2023-04-27 (Crawled : 11:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -4.2%
H: 2.45%
C: -9.11%
liver association update program study
Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH
Published: 2023-03-10 (Crawled : 14:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -1.71%
H: 0.27%
C: -12.44%
treatment fda fibrosis liver meeting nash
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
Published: 2023-01-19 (Crawled : 15:20) - biospace.com/
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -0.13%
H: 1.27%
C: -1.85%
treatment fda fibrosis drug liver application nash
Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
Published: 2023-01-04 (Crawled : 14:20) - biospace.com/
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: 0.24%
H: 5.02%
C: 2.31%
fibrosis liver conference nash study
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
Published: 2022-12-23 (Crawled : 13:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: 1.41%
H: 1.83%
C: -13.4%
fda fibrosis drug liver application nash
New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease
Published: 2022-12-08 (Crawled : 00:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -0.41%
H: 1.37%
C: 0.27%
liver disease study
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022
Published: 2022-11-06 (Crawled : 16:20) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
| Email alert
Add to watchlist
meeting liver
Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022
Published: 2022-10-31 (Crawled : 00:00) - biospace.com/
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: -2.39%
meeting fibrosis liver nash
Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
Published: 2022-06-21 (Crawled : 12:00) - biospace.com/
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: 7.77%
H: 0.0%
C: 0.0%
liver international
Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH
Published: 2021-12-09 (Crawled : 12:30) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -2.98%
H: 1.27%
C: -12.15%
ema fibrosis application liver authorization nash
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.